Posted: March 21, 2017
Montana and Iowa recently joined the now 28 states to provide pathways for access to Biosimilars, and create much needed patient safety rules, including guidelines for dispensing pharmacists to communicate to physicians about biosimilar substitutions. New Mexico passed HB260 and waits to become the 29th state to enact legislation upon the Governor’s signature. Here are the statuses of legislation in states across the country.
Montana: HB233
Status: Signed by the Governor
Iowa: HF305
Status: Signed by the Governor
Alaska: SB32
Status: Passed the Senate Labor & Commerce Committee
Alabama: HB82
Status: Assigned to House Health Committee
Arkansas: HB1204
Status: Amended and Assigned to House Public Health, Welfare & Labor Committee
Connecticut: HB7118
Status: Filed with Legislative Commissioner’s Office
Kansas: HB2107
Status: Passed the House and referred to Senate Committee on Public Health and Welfare. Held a Hearing on Thursday, March 16. CSRO testified and was a listed proponent
Nebraska: LB481
Status: Referred to Health and Human Services Committee, and listed as a priority bill
Nevada: AB245
Status: Assigned to Committee on Commerce and Labor, hearing scheduled for March 22
New Mexico: HB260
Status: Passed both chambers, awaits Governor’s signature
New York: HB4788
Status: Referred to House Higher Education Committee
South Carolina: H3438
Status: Passed House unanimously (104-0) and passed the Senate Medical Affairs Committee
Wyoming: SF121
Status: Passed the Senate and House
Alabama: HB82
Status: Referred to House Health Committee
Minnesota: HF712
Status: Passed House Committee, on 2nd Reading on the House Floor
Maryland: SB997/HB1273
Status: Passed the Senate – SB997
Status: Passed the House – HB1273
Vermont: S.92
Status: Passed the Senate Health and Welfare Committee
